Robert W. Baird Issues Positive Forecast for LivaNova (NASDAQ:LIVN) Stock Price

LivaNova (NASDAQ:LIVN) had its price target lifted by Robert W. Baird from $66.00 to $72.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have an outperform rating on the stock.

A number of other research analysts also recently weighed in on LIVN. The Goldman Sachs Group initiated coverage on LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 price target on the stock. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Stifel Nicolaus lifted their price target on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Finally, Needham & Company LLC lifted their price target on LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $69.17.

LivaNova Stock Down 0.9 %

Shares of LivaNova stock opened at $51.13 on Thursday. The stock’s fifty day moving average is $51.13 and its 200-day moving average is $53.13. The firm has a market capitalization of $2.78 billion, a PE ratio of 121.74 and a beta of 1.01. The company has a quick ratio of 2.94, a current ratio of 3.37 and a debt-to-equity ratio of 0.49. LivaNova has a 12-month low of $42.75 and a 12-month high of $64.47.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Primecap Management Co. CA grew its stake in LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock valued at $327,889,000 after purchasing an additional 44,049 shares in the last quarter. Vanguard Group Inc. grew its stake in LivaNova by 3.5% in the first quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock valued at $102,537,000 after purchasing an additional 62,480 shares in the last quarter. Point72 Asset Management L.P. grew its stake in LivaNova by 204.3% in the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock valued at $70,479,000 after purchasing an additional 863,157 shares in the last quarter. Magnetar Financial LLC grew its stake in LivaNova by 8.1% in the second quarter. Magnetar Financial LLC now owns 814,452 shares of the company’s stock valued at $44,648,000 after purchasing an additional 61,114 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of LivaNova by 3.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company’s stock worth $41,889,000 after buying an additional 25,277 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.